Skip to main content

Treatment Clinical Trials for Prostate Cancer

Review the prostate cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 251-275 of 319

Inhibiting Nerve Activity with Ethanol for the Treatment of High-risk Localized Prostate Cancer
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Two Fraction SBRT with Dominant Lesion SIB for the Treatment of Localized Prostate Cancer
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
A Vaccine (PGV001) in Combination with Immunotherapy (CDX-301 and Poly-ICLC) for the Treatment of Prostate Cancer
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Dapagliflozin Propanediol for the Treatment of Localized Prostate Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Image-guided Focal Brachytherapy with Combined 18F-DCFPyl PET/CT for the Treatment of Patients with Localized Prostate Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients with PSCA+ Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
An Extended Course of Sipuleucel-T Immunotherapy for Treating Patients with Metastatic Castration-resistant Prostate Cancer, EXCITE Trial
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Oligometastatic Prostate Cancer
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
REGN5678 and Cemiplimab for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
177^Lu-PSMA-617 in Combination with Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Stereotactic Body Radiation Therapy for the Treatment of Patients with Advanced Prostate Cancer, PRORAD-5 Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cabozantinib in Combination with Lutetium-177 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, CaboLu Study
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Gamitrinib for the Treatment of Advanced or Refractory Solid Tumors or Lymphoma
Status: Active
Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania
pTVG-HP DNA Vaccine + Nivolumab + Targeted Radiation Therapy to Resistant Lesions for the Treatment of Biochemically Recurrent, Oligometastatic Prostate Cancer
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
CBP-1019 with FOLFOX with or without Bevacizumab, Pembrolizumab, or Enzalutamide for the Treatment of Metastatic Solid Tumors of Epithelial Origin
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Status: Active
Location: 5 locations
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Cancer Patients
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tumor Treating Fields Therapy (NovoTTF™-200M and NovoTTF-200A Systems) for the Treatment of Refractory Spinal Metastasis
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Differences in Immunological Effects of Vitamin D Replacement among African American Prostate Cancer Patients with Localized versus Metastatic Disease
Status: Active
Location: 2 locations
Pre-Surgical Tirzepatide-Assisted Weight Loss for the Treatment of Overweight and Obese Men with Diabetes and Prostate Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas